• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Dascena Labs Announces Partnership with Concentric By Ginkgo to Scale COVID Response Through K-12 Classroom Testing

Share:

March 30, 2021

As more and more schools work to support in-person learning environments, communities across the country have turned to COVID-19 testing programs to monitor the virus. Even as teachers and guardians become eligible for and receive effective and safe vaccines, clinical vaccine trials for individuals under 16 are just beginning, and efforts to track and mitigate viral spread remain critical.

Dascena Labs, which is supporting the urgent needs of the country by offering free COVID-19 testing to patients nationwide, has partnered with Concentric by Ginkgo to provide a scalable, effective and simple testing modality – pooled testing – to serve these communities.

Concentric by Ginkgo is Ginkgo Bioworks, Inc.’s (“Ginkgo”) biosecurity and public health effort and a national testing provider for K-12 schools. Concentric by Ginkgo currently serves hundreds of communities in over a dozen states. Concentric’s goal is to provide easy, affordable pooled testing to every school in America. Pooled classroom testing, which combines swabs from all consenting individuals in a classroom and runs them as a single test, is an effective way to significantly increase testing capacity and lower the cost of testing programs.

“We are very excited to partner with Ginkgo on this highly important initiative as our country continues to work to recover from the ongoing COVID-19 crisis,” said James Wingrove, Ph.D., chief scientific officer of Dascena, Inc., who oversees Dascena Labs. “Enabling the safe return of children and teachers back to in-person learning is a crucial step in that recovery. By providing accessible and accurate testing to teachers and students, we hope, that together with Ginkgo, we can help to provide safe learning environments.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Dascena Labs was launched by Dascena, Inc., a company developing machine learning algorithms to enable early disease intervention and improve care outcomes for patients, in late 2020 in response to addressing the COVID-19 health crisis. Dascena Labs provides COVID-19 PCR testing to individuals through its COVID-19 sample collection sites across the US, as well as algorithm-driven COVID-19 population management and molecular testing solutions to enterprises, communities, and healthcare providers. Dascena Labs operates seven days per week and has scaled capacity to process a growing number of PCR samples. Since its inception, the lab has processed over 720,000 samples, supporting communities across the US.

“We are proud to offer testing that can contribute to the confidence and data-driven decision-making of communities working to return to in-person learning,” said Jason Kelly, CEO, and co-founder of Ginkgo. “Testing should be available to every student, every week, in every school that needs it – and we’re confident that the significant funding for school testing announced by the Biden administration last week will support communities during this vital phase of pandemic response.”

To learn more about Concentric by Ginkgo or to get your school district involved, head over to concentricbyginkgo.com.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Thermo Fisher Scientific Confirms Offer to Acquire QIAGEN Shares Expires on August 10Thermo Fisher Scientific Confirms Offer to Acquire QIAGEN Shares Expires on August 10
  • Q1 2023 Digital Health Funding Reaches $3.4B Across 132 DealsQ1 2023 Digital Health Funding Reaches $3.4B Across 132 Deals
  • FDA approves first generic EpiPen autoinjectorFDA approves first generic EpiPen autoinjector
  • 15 digital health mergers, acquisitions from Q2 201815 digital health mergers, acquisitions from Q2 2018
  • Veristat Expands Pharmacovigilance and Safety Services with Acquisition of Certus PVVeristat Expands Pharmacovigilance and Safety Services with Acquisition of Certus PV
  • OptumHealth Acquires Post-Acute Care Management Platform naviHealthOptumHealth Acquires Post-Acute Care Management Platform naviHealth
  • Owlet Releases New Baby Sleep Monitoring System Dream DuoOwlet Releases New Baby Sleep Monitoring System Dream Duo
  • Eli Lilly Drops $50 Million+ for Entos’ TechEli Lilly Drops $50 Million+ for Entos’ Tech

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications